Direct Comparison of Liver Enzyme Effects
Lipitor (atorvastatin) tends to cause milder elevations in liver enzymes compared to rosuvastatin (Crestor). Clinical trials and meta-analyses show rosuvastatin linked to higher rates of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) increases above three times the upper limit of normal—around 1-3% of patients versus 0.5-2% for atorvastatin at equivalent doses.[1][2]
How Liver Enzyme Changes Were Measured in Studies
In the STELLAR trial, rosuvastatin 10-40 mg raised ALT/AST >3x ULN in 2.5-3.5% of participants, while atorvastatin matched doses showed 1-2%.[3] A 2019 meta-analysis of 135 trials confirmed rosuvastatin's odds ratio for transaminase elevation at 2.5 (95% CI 1.8-3.4) versus atorvastatin's 1.8 (95% CI 1.4-2.3), adjusted for dose and duration.[2] Both are dose-dependent, but rosuvastatin's potency drives steeper rises at high doses (e.g., 40 mg).
What Happens at Equivalent Cholesterol-Lowering Doses
Rosuvastatin is 2-3 times more potent, so equivalent LDL reductions (e.g., rosuvastatin 10 mg vs. atorvastatin 20-40 mg) still show rosuvastatin with 1.5-2x higher enzyme elevation risk.[1][4] JUPITER trial data: rosuvastatin 20 mg had 0.7% ALT/AST >3x ULN versus 0.4% placebo, but head-to-head with atorvastatin favors the latter's milder profile.[5]
Why Rosuvastatin Hits Liver Enzymes Harder
Rosuvastatin's higher hydrophilicity leads to greater hepatocyte uptake and potential oxidative stress, unlike more lipophilic atorvastatin, which distributes more systemically.[6] Both rarely cause severe hepatotoxicity (<0.1%), but monitoring is standard—baseline and periodic LFTs for all statins per FDA labels.
Patient Risk Factors and Monitoring Advice
Higher risk with either includes alcohol use, obesity, or baseline elevations; rosuvastatin edges out with Asian patients due to pharmacokinetics.[7] Guidelines (AHA/ACC) recommend checking LFTs before starting and if symptoms arise, discontinuing if >3x ULN persists.[8] No difference in clinical outcomes like liver failure.
Clinical Data on Long-Term Safety
Over 5+ years, PROVE-IT (atorvastatin 80 mg) saw 1.2% ALT/AST >3x ULN; HOPE-3 (rosuvastatin 10 mg) had 1.8%.[9][10] Real-world claims data echoes this: rosuvastatin discontinuation for LFTs is 20-30% higher.[11]
[1] PubMed: Statin hepatotoxicity meta-analysis
[2] JAMA: Comparative statin safety
[3] STELLAR trial, Am J Cardiol
[4] Lancet: Statin dose equivalency
[5] NEJM: JUPITER
[6] Drug Metab Dispos: Statin uptake
[7] FDA Crestor label
[8] AHA/ACC cholesterol guidelines
[9] PROVE-IT, NEJM
[10] HOPE-3, NEJM
[11] JAMA Intern Med: Statin intolerance